SG11202109568TA - Pyridazinones and methods of use thereof - Google Patents

Pyridazinones and methods of use thereof

Info

Publication number
SG11202109568TA
SG11202109568TA SG11202109568TA SG11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA
Authority
SG
Singapore
Prior art keywords
pyridazinones
methods
Prior art date
Application number
Inventor
John Reilly
Liron Walsh
Peter Mundel
Amy Westerling-Bui
Matthew Daniels
Maolin Yu
Mark Ledeboer
Jean-Christophe Harmange
Gal Marie-Francoise Coeffet-Le
Michael Broxson
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of SG11202109568TA publication Critical patent/SG11202109568TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202109568T 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof SG11202109568TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821178P 2019-03-20 2019-03-20
PCT/US2020/023369 WO2020191056A1 (en) 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202109568TA true SG11202109568TA (en) 2021-10-28

Family

ID=72519163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109568T SG11202109568TA (en) 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof

Country Status (11)

Country Link
US (1) US20220152031A1 (en)
EP (1) EP3941475A4 (en)
JP (1) JP2022525506A (en)
CN (1) CN113939295A (en)
AU (1) AU2020240059A1 (en)
CA (1) CA3132580A1 (en)
IL (1) IL286481A (en)
MA (1) MA55381A (en)
MX (1) MX2021011316A (en)
SG (1) SG11202109568TA (en)
WO (1) WO2020191056A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210069652A (en) * 2018-09-18 2021-06-11 골드핀치 바이오 인코포레이티드 Pyridazinone and methods of use thereof
KR20230028522A (en) * 2020-07-03 2023-02-28 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Heterocyclic compounds and their uses
CN117940417A (en) * 2021-09-10 2024-04-26 南京明德新药研发有限公司 Halogen substituted pyridazinone compounds and application thereof
CN114235972B (en) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 Method for determining content of linagliptin impurity RBP-1
WO2024027752A1 (en) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 Pharmaceutical composition comprising heterocyclic compound, preparation method therefor, and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2099743A1 (en) * 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
CA2180253A1 (en) * 1993-12-29 1995-07-06 Atsushi Akahane Pyrazolopyridine adenosine antagonists
JPH09216883A (en) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd Pyrazolopyridine compound and medicine containing the same compound
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
AU2005206562A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2005295729B2 (en) * 2004-10-13 2011-07-14 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US20080175794A1 (en) * 2005-01-25 2008-07-24 Neurogen Corporation Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues
DK1959951T3 (en) * 2005-12-01 2010-03-01 Hoffmann La Roche Heteroberl-substituted piperidine derivatives as L-CPT1 inhibitors
US20090227588A1 (en) * 2005-12-05 2009-09-10 Roman Wolfgang Fleck Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
DE102007032507A1 (en) * 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007061963A1 (en) * 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
US8324199B2 (en) * 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
WO2009117157A1 (en) * 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
DE102008062826A1 (en) * 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
TW201444844A (en) * 2013-03-14 2014-12-01 Hydra Biosciences Inc Substituted xanthines and methods of use thereof
EP2881390A1 (en) * 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
JP6667093B2 (en) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ Pyrid [2,3-d] pyrimidine-2,4 (1H, 3H) -dione derivatives
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Also Published As

Publication number Publication date
US20220152031A1 (en) 2022-05-19
WO2020191056A8 (en) 2021-09-30
AU2020240059A1 (en) 2021-10-28
MA55381A (en) 2022-01-26
JP2022525506A (en) 2022-05-17
EP3941475A4 (en) 2023-01-25
CN113939295A (en) 2022-01-14
WO2020191056A1 (en) 2020-09-24
MX2021011316A (en) 2021-10-13
IL286481A (en) 2021-12-01
EP3941475A1 (en) 2022-01-26
CA3132580A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3684364A4 (en) Pyridazinones and methods of use thereof
IL281438A (en) Pyridazinones and methods of use thereof
IL286481A (en) Pyridazinones and methods of use thereof
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287973A (en) Acss2 inhibitors and methods of use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
EP3752166A4 (en) Trialkyne linking agents and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL281866A (en) Introducer devices and methods of use thereof
SG11202100533VA (en) Hepato-biliary-pancreatic tissues and methods of making same
IL283782A (en) Anellosomes and methods of use
IL291730A (en) Protein-macromolecule conjugates and methods of use thereof
IL280000A (en) Tumor reduction formulations and methods of use thereof
EP3765485A4 (en) Immuno-exosomes and methods of use thereof
EP3761989A4 (en) Imidazodiazepinediones and methods of use thereof
IL276792A (en) Inhaler and methods of use thereof
IL276053A (en) Therapeutic-gard and method of use thereof
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
GB2589398B (en) Compounds and methods of use
IL283231A (en) Dpep-1 binding agents and methods of use
EP3836966A4 (en) Catabodies and methods of use thereof
EP3867386A4 (en) Brassica event mon94100 and methods of use thereof